Competition and Market Dynamics - The company faces competition from numerous pharmaceutical companies, including large global manufacturers, and generic products [109]. - The wholesale distributor network has seen increasing consolidation, leading to pricing pressure and a shift in sales to competitors [112]. - The company faces substantial competition from major pharmaceutical and biotechnology companies, which could adversely affect profitability and market share [131]. - The approval of generic products often leads to immediate competition, resulting in lower prices and reduced margins, which could adversely affect profitability [163]. - The concentration of net revenues among four customers, which accounted for 64% of total revenues in 2024, poses risks related to customer consolidation and pricing pressures [236]. Financial Performance and Risks - The company expects to spend significant resources on research and development, which may not result in marketable products [128]. - The company is subject to risks related to product liability claims that may not be covered by insurance [128]. - Medicaid rebate accruals have significantly increased due to acquisitions and sales of branded products, which could adversely affect the company's financial position and operating results [166]. - Accruals for the Medicare Coverage Gap Discount Program have also increased, potentially decreasing revenues from product sales and impacting the company's financial health [167]. - The company faces complex reporting obligations under the Medicaid rebate program, with potential penalties for non-compliance that could adversely affect financial results [237]. Regulatory and Compliance Challenges - The company may face legal and regulatory challenges, including false claims litigation, which could result in significant penalties [131]. - The company is subject to various U.S. laws, including the Anti-Kickback Statute and false claims laws, which could lead to significant penalties and affect operations [148]. - Increased enforcement activities by agencies like the FDA and DOJ could result in investigations that adversely impact the company's financial condition and operations [149]. - Compliance with FDA regulations and potential violations could lead to sanctions, including fines and product recalls, impacting business operations [257]. - The company is subject to extensive regulations governing the use and disposal of hazardous materials, which may incur significant compliance costs [259]. Research and Development - The company expects to invest significantly in research and development, but there is no guarantee that these efforts will result in marketable products, which could adversely affect financial results [168]. - The company faces risks related to the timely development and commercialization of new products, which are critical for future revenue growth and profitability [160]. - Clinical trials, such as the NEW DAY trial for ILUVIEN, may fail to demonstrate efficacy or take longer than anticipated, which could negatively impact the company's financial condition and cash flows [171]. - The company relies on third parties for clinical trials, and any failure in their performance could delay or terminate trials, affecting regulatory approval and commercialization [172]. Workforce and Diversity - The company’s workforce consists of 897 employees, with 720 located in the U.S. and 177 in other countries [118]. - Approximately 42% of the workforce identified as female and 45% identified as a person of color or indigenous person as of the end of 2024 [120]. Mergers and Acquisitions - The acquisition of Alimera was completed on September 16, 2024, with anticipated benefits including enhanced revenues and a strengthened market position [210]. - The merger has materially increased the size of operations, and effective management of these expanded operations is crucial to avoid adverse effects on stock price [211]. - The company faces significant costs and expenses related to the merger, including professional services and transaction costs, which may affect liquidity and cash flow [213]. - The success of the combined company will depend on maintaining relationships with third parties and customers, which may be affected by public attitudes towards the merger [211]. Supply Chain and Manufacturing - The company relies on third-party manufacturers for many products, which poses risks related to compliance and production delays [141]. - The company operates three manufacturing facilities, and any disruption could impair production and shipping, leading to potential "failure to supply" claims from customers [169]. - The company is dependent on imported active pharmaceutical ingredients (APIs), and any disruptions in supply or increased costs could materially impact revenues and operations [243]. - The DEA regulates the supply of APIs for controlled substances, and any inability to obtain necessary approvals could significantly reduce revenues from these products [245]. Legal and Intellectual Property Risks - The company faces risks related to climate change, which could disrupt operations and adversely affect client activity levels and creditworthiness [175]. - There is a risk of litigation regarding patent infringement, which could divert resources and delay product commercialization [192]. - The company may need to seek licenses from third parties due to potential patent infringement claims, which could impose significant costs [194]. - The company's success largely depends on the ability to obtain and maintain intellectual property protection, which is uncertain in the biotechnology and pharmaceuticals field [188]. Financial Obligations and Debt - As of December 31, 2024, the company had approximately $639.2 million in indebtedness and other liabilities on a consolidated basis [284]. - The New Credit Agreement includes a $325.0 million term loan and a $75.0 million revolving credit facility, secured by all assets [285]. - The company may struggle to repurchase Senior Notes or pay cash amounts due upon maturity or conversion, potentially leading to defaults [293]. - The New Credit Agreement includes restrictive covenants that limit the company's operational flexibility and ability to incur additional debt [287]. Market and Economic Conditions - The company faces risks from international operations, including economic conditions and geopolitical tensions, which could adversely affect business results [262]. - Inflationary pressures may significantly increase input costs, which the company may not be able to pass on to customers [270]. - Changes in third-party payer coverage and reimbursement practices may hinder the company's ability to market products effectively [254].

Financial Performance - Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%[1] - Purified Cortrophin® Gel net revenues reached $52.6 million, an increase of 76.8% year-over-year[1] - Adjusted non-GAAP net income for Q3 2024 was $148.3 million, compared to $131.8 million in Q3 2023, representing a year-over-year increase of 12.5%[41] - Net revenues for the three months ended September 30, 2024, were $148,332 thousand, up from $131,829 thousand in 2023, reflecting an increase of approximately 12.5%[43] - Adjusted non-GAAP EBITDA for Q3 2024 was $35.1 million, a decrease of 3.8% compared to the same period in 2023[14] - Adjusted non-GAAP EBITDA for the three months ended September 30, 2024, was $35,104 thousand, slightly down from $36,484 thousand in 2023[44] Expenses and Losses - Selling, general, and administrative expenses increased 88.2% to $79.1 million, primarily due to increased employment-related costs and acquisition-related expenses[12] - Total operating expenses for Q3 2024 were $168.9 million, up from $113.9 million in Q3 2023, reflecting a significant increase of 48.3%[41] - Research and development expenses decreased to $10.1 million in Q3 2024 from $11.1 million in Q3 2023, a decline of 9.0%[41] - The net loss for Q3 2024 was $24.2 million, compared to a net income of $9.9 million in Q3 2023, indicating a significant shift in profitability[41] - Basic and diluted loss per share for Q3 2024 was $(1.27), compared to earnings of $0.46 per share in Q3 2023[41] - The company incurred M&A transaction and integration expenses of $9,945 thousand for the three months ended September 30, 2024, compared to $165 thousand in 2023, indicating a significant increase in costs associated with mergers and acquisitions[44] Guidance and Future Expectations - Increased 2024 guidance with expected net revenues of $594 million to $602 million, up from previous guidance of $540 million to $560 million[17] - Cortrophin Gel net revenues guidance for 2024 is $196 million to $200 million, representing year-over-year growth of 75% to 78%[17] - The company expects to capture approximately $10 million of identified cost synergies from the Alimera acquisition in 2025[5] Acquisitions and Business Expansion - Completed the acquisition of Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® to the Rare Disease portfolio[1] - The company is focused on expanding its Rare Disease business, which includes novel products in various therapeutic areas[36] Cash and Assets - As of September 30, 2024, the company had $145.0 million in unrestricted cash and cash equivalents[15] - As of September 30, 2024, total assets increased to $1,287,377 thousand from $904,422 thousand as of December 31, 2023, representing a growth of approximately 42.4%[42] - The company’s cash and cash equivalents decreased to $144,982 thousand as of September 30, 2024, from $221,121 thousand as of December 31, 2023, a decline of approximately 34.3%[42] Liabilities and Equity - Total current liabilities rose to $189,933 thousand as of September 30, 2024, compared to $145,477 thousand as of December 31, 2023, indicating an increase of about 30.5%[42] - Non-current liabilities increased to $312,918 thousand as of September 30, 2024, from $284,819 thousand as of December 31, 2023, reflecting a growth of approximately 9.9%[42] - The company reported a total stockholders' equity of $405,948 thousand as of September 30, 2024, down from $432,749 thousand as of December 31, 2023, a decrease of about 6.2%[42] Other Financial Metrics - Total depreciation and amortization expenses for the three months ended September 30, 2024, were $15.748 million, slightly up from $15.207 million in the same period of 2023[47] - Stock-based compensation for the three months ended September 30, 2024, was $7.484 million, compared to $5.444 million in the same period of 2023[47] - The diluted weighted-average shares outstanding increased to 19.404 million for the three months ended September 30, 2024, from 19.125 million in the same period of 2023[47] Risks and Challenges - Risks include the ability to achieve commercial success with Cortrophin Gel and the impact of supply chain disruptions on production[39] - The impact of Canada operations included revenues and expenses that will not recur after the closure of operations, which was completed as of March 31, 2023[47] - The company recorded a loss on extinguishment of debt of $7.468 million for the three months ended September 30, 2024[47] - The unrealized gain on investment in equity securities for the three months ended September 30, 2024, was a loss of $1.355 million, with no comparable figure in the same period of 2023[47]

Financial Performance and Key Metrics - The company reported total revenues of $148.3 million for Q3 2024, an increase of 13% compared to Q3 2023, driven by strong demand for Cortrophin Gel and growth in generics [12][28] - Adjusted non-GAAP EBITDA was $35.1 million, while adjusted non-GAAP EPS was $1.34, compared to $1.27 in the prior year [36] - Cortrophin Gel generated $52.6 million in revenues, up 77% year-over-year, with the highest number of new patient starts and unique prescribers since its launch [13][28] Business Line Performance - The generics business achieved revenues of $78.2 million, an increase of 11% over the prior year, reflecting strength in the base business and contributions from new product launches [14][31] - Revenues from established brands and other segments were $13.7 million, a decrease of 57% year-over-year, aligning with expectations [31] Market Data and Key Metrics - The overall ACTH category is expected to deliver more than 20% year-over-year growth in 2024, with Cortrophin Gel on a strong multi-year growth trajectory [14][50] - The company expects to capture $10 million in synergies from the Alimera acquisition by 2025, contributing to adjusted non-GAAP EBITDA of $35 million to $38 million [11][39] Company Strategy and Industry Competition - The acquisition of Alimera is seen as transformative for the Rare Disease business, with expectations of substantial shareholder value creation [11][39] - The company is focused on integrating the Alimera products and leveraging its expanded sales force to drive growth in ophthalmology and other specialties [9][27] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Cortrophin Gel and the overall Rare Disease segment, anticipating it to be the largest business unit and growth driver in 2025 [27][66] - The company raised its full-year 2024 guidance, reflecting continued strength in Cortrophin Gel and contributions from ILUVIEN and YUTIQ [39][40] Other Important Information - The company ended the quarter with $145 million in unrestricted cash and $641.3 million in outstanding debt, with gross leverage at approximately 3.8 times [37] - Non-GAAP gross margin was reported at 60%, a decrease of approximately 3.9 points from the prior year, primarily due to an unfavorable product mix [33] Q&A Session Summary Question: Can you talk about the payer landscape for Cortrophin Gel? - Management noted that the payer landscape is evolving, with increased affordability for seniors expected to improve patient access [48] Question: What is the mix of growth from existing versus new prescribers for Cortrophin? - Growth has come from both existing prescribers moving away from competitors and new prescribers unique to Cortrophin Gel [49][50] Question: What does the cadence of new launches for generics look like for 2025? - The company expects to continue a strong cadence of new launches, projecting growth in the high-single-digits to low double-digits for the generics business [51] Question: What is the expected quarterly run rate for ILUVIEN and YUTIQ going into next year? - Management indicated that the Q4 guidance reflects a transition period, with expectations for growth in 2025 [56] Question: How is the combined sales team impacting Cortrophin in ophthalmology? - Early signs are positive, and management remains confident in growth from the combined sales force [62] Question: What lessons were learned from the Alimera acquisition? - The company emphasized the importance of strategic alignment and addressing challenges effectively during acquisitions [68][70]

PART I — FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, with detailed notes on business, acquisitions, and debt for the reported periods [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows a significant increase in total assets and liabilities from December 31, 2023, to September 30, 2024, primarily driven by the Alimera acquisition and related financing | Metric | Sep 30, 2024 (in thousands) | Dec 31, 2023 (in thousands) | Change (in thousands) | | :-------------------------------- | :-------------------------- | :-------------------------- | :-------------------- | | Total Assets | $1,287,377 | $904,422 | $382,955 | | Total Liabilities | $856,579 | $446,823 | $409,756 | | Total Stockholders' Equity | $405,948 | $432,749 | $(26,801) | - **Intangible assets, net**, increased significantly from **$209,009 thousand** to **$569,825 thousand**, and **Goodwill** increased from **$28,221 thousand** to **$60,426 thousand**, largely due to the **Alimera acquisition**[9](index=9&type=chunk) - **Non-current convertible notes, net**, appeared at **$305,293 thousand** as of September 30, 2024, with no balance at December 31, 2023, reflecting **new financing**[9](index=9&type=chunk) [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three and nine months ended September 30, 2024, the company reported a net loss, a significant shift from net income in the prior year periods, despite increased net revenues, primarily due to higher operating expenses and a loss on debt extinguishment | Metric | 3 Months Ended Sep 30, 2024 (in thousands) | 3 Months Ended Sep 30, 2023 (in thousands) | Change (in thousands) | % Change | | :-------------------------------------- | :----------------------------------------- | :----------------------------------------- | :-------------------- | :------- | | Net Revenues | $148,332 | $131,829 | $16,503 | 12.5% | | Operating (loss) income | $(20,519) | $17,948 | $(38,467) | -214.4% | | Net (Loss) Income | $(24,166) | $9,940 | $(34,106) | -343.1% | | Basic (Loss) Income Per Share | $(1.27) | $0.46 | $(1.73) | -376.1% | | Metric | 9 Months Ended Sep 30, 2024 (in thousands) | 9 Months Ended Sep 30, 2023 (in thousands) | Change (in thousands) | % Change | | :-------------------------------------- | :----------------------------------------- | :----------------------------------------- | :----------------------------------------- | :------- | | Net Revenues | $423,802 | $355,162 | $68,640 | 19.3% | | Operating (loss) income | $4,962 | $40,245 | $(35,283) | -87.7% | | Net (Loss) Income | $(8,246) | $17,624 | $(25,870) | -146.8% | | Basic (Loss) Income Per Share | $(0.49) | $0.84 | $(1.33) | -158.3% | - **Selling, general, and administrative expenses** increased significantly by **88.2%** for the three months and **53.5%** for the nine months ended September 30, 2024, compared to the prior year, largely due to **Alimera acquisition-related costs** and increased **Rare Disease sales and marketing**[11](index=11&type=chunk)[252](index=252&type=chunk)[270](index=270&type=chunk) - A **loss on extinguishment of debt** of **$7,468 thousand** was recognized for both the three and nine months ended September 30, 2024, due to the repayment of the **Truist Credit Facility**[11](index=11&type=chunk)[259](index=259&type=chunk)[279](index=279&type=chunk) [Condensed Consolidated Statements of Comprehensive (Loss) Income](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20(Loss)%20Income) The company reported a total comprehensive loss for both the three and nine months ended September 30, 2024, primarily driven by the net loss and a significant loss on interest rate swaps, contrasting with comprehensive income in the prior year | Metric | 3 Months Ended Sep 30, 2024 (in thousands) | 3 Months Ended Sep 30, 2023 (in thousands) | Change (in thousands) | | :-------------------------------------- | :----------------------------------------- | :----------------------------------------- | :-------------------- | | Net (Loss) Income | $(24,166) | $9,940 | $(34,106) | | Total other comprehensive (loss) income, net of tax | $(2,962) | $350 | $(3,312) | | Total comprehensive (loss) income, net of tax | $(27,128) | $10,290 | $(37,418) | - **Loss on interest rate swap** was **$(2,862) thousand** for the three months and **$(3,282) thousand** for the nine months ended September 30, 2024, compared to gains in the prior year[13](index=13&type=chunk) [Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Mezzanine%20Equity%20and%20Stockholders'%20Equity) The statements reflect a decrease in total stockholders' equity from December 31, 2023, to September 30, 2024, primarily due to the net loss and other comprehensive loss, partially offset by stock-based compensation | Metric | Sep 30, 2024 (in thousands) | Dec 31, 2023 (in thousands) | Change (in thousands) | | :-------------------------------- | :-------------------------- | :-------------------------- | :-------------------- | | Total Stockholders' Equity | $430,798 | $457,599 | $(26,801) | | Additional paid-in capital | $510,899 | $514,103 | $(3,204) | | Accumulated deficit | $(89,597) | $(80,132) | $(9,465) | | Accumulated other comprehensive income, net of tax | $5,366 | $8,857 | $(3,491) | - **Stock-based compensation expense** contributed **$22,283 thousand** to **additional paid-in capital** for the nine months ended September 30, 2024[16](index=16&type=chunk) - **Treasury stock purchases** for **restricted stock vests** amounted to **$(10,641) thousand** for the nine months ended September 30, 2024[16](index=16&type=chunk) - A **Capped Call Transaction**, net of tax, resulted in a **$(30,275) thousand** reduction in **additional paid-in capital** for the nine months ended September 30, 2024[16](index=16&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities decreased for the nine months ended September 30, 2024, compared to the prior year, while investing activities saw a significant increase in cash used due to the Alimera acquisition, and financing activities provided substantial cash through new debt and convertible notes | Metric | 9 Months Ended Sep 30, 2024 (in thousands) | 9 Months Ended Sep 30, 2023 (in thousands) | Change (in thousands) | | :--------------------------------------------------- | :----------------------------------------- | :----------------------------------------- | :-------------------- | | Net Cash and Cash Equivalents Provided by Operating Activities | $48,157 | $74,219 | $(26,062) | | Net Cash and Cash Equivalents Used in Investing Activities | $(394,038) | $(13,732) | $(380,306) | | Net Cash and Cash Equivalents Provided by Financing Activities | $269,852 | $79,357 | $190,495 | | Net Change in Cash, Cash Equivalents, and Restricted Cash | $(76,104) | $139,844 | $(215,948) | - **Acquisition of Alimera**, net of cash acquired, used **$(393,079) thousand** in investing activities[18](index=18&type=chunk) - **Proceeds from convertible notes** were **$316,250 thousand** and from **term loan** were **$325,000 thousand** in financing activities[18](index=18&type=chunk) - **Repayment on borrowings under credit agreement** was **$(292,500) thousand**, and **purchase of capped call transaction** was **$(40,575) thousand**[18](index=18&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=13&type=section

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Les Sulewski - Truist Securities Gary Nachman - Raymond James & Associates Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright & Co. Tim Chiang - Capital One Operator Good day, everyone, and welcome to today's ANI Pharm ...

[PART I — FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20%E2%80%94FINANCIAL%20INFORMATION) This section presents the unaudited condensed consolidated financial statements and management's discussion and analysis for ANI Pharmaceuticals, Inc [Condensed Consolidated Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements, including balance sheets, income statements, and cash flows, along with detailed notes [Condensed Consolidated Financial Statements](index=5&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This subsection contains the core unaudited financial tables for the period, including balance sheets, statements of operations, and cash flows Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total Assets** | **$920,753** | **$904,422** | | Cash and cash equivalents | $240,110 | $221,121 | | Inventories | $125,448 | $111,196 | | Intangible assets, net | $183,078 | $209,009 | | **Total Liabilities** | **$440,143** | **$446,823** | | Non-current debt, net | $284,394 | $284,819 | | **Total Stockholders' Equity** | **$455,760** | **$432,749** | Condensed Consolidated Statements of Operations Highlights (in thousands, except per share) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | **Net Revenues** | **$138,040** | **$116,547** | **$275,470** | **$223,333** | | Operating Income | $5,169 | $12,402 | $25,481 | $22,297 | | **Net (Loss) Income** | **($2,287)** | **$6,245** | **$15,920** | **$7,684** | | Diluted (Loss) Income Per Share | ($0.14) | $0.29 | $0.70 | $0.36 | Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | | Net Cash Provided by Operating Activities | $35,683 | $42,050 | | Net Cash Provided by (Used in) Investing Activities | $4,484 | ($9,179) | | Net Cash (Used in) Provided by Financing Activities | ($21,178) | $75,602 | | **Net Change in Cash** | **$18,989** | **$108,473** | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of accounting policies and specific line items, covering the Alimera merger, restructuring, debt, and legal contingencies - On June 21, 2024, the company entered into an agreement to acquire Alimera Sciences, Inc. for **$5.50 per share in cash** plus a contingent value right (CVR)[52](index=52&type=chunk)[53](index=53&type=chunk) - The Alimera transaction will be financed with **$280.0 million in committed debt**, incurring approximately **$3.5 million in transaction costs** in Q2 2024[57](index=57&type=chunk) - The company sold its Oakville, Ontario property on March 28, 2024, for approximately **$14.2 million**, resulting in a gain of approximately **$5.3 million**[61](index=61&type=chunk) Revenue by Segment (in thousands) | Segment | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Generics, Established Brands, and Other | $88,847 | $189,340 | | Rare Disease | $49,193 | $86,130 | | **Total Net Revenues** | **$138,040** | **$275,470** | - As of June 30, 2024, the company had **$292.5 million in principal outstanding** on its Term Facility with an interest rate of **11.44%**[64](index=64&type=chunk) - The **$40.0 million Revolving Facility** remained undrawn as of June 30, 2024[66](index=66&type=chunk) - The company is involved in several legal proceedings, including a royalty dispute with CG Oncology, patent litigation regarding a pitolisant hydrochloride drug product, and various ranitidine-related lawsuits[128](index=128&type=chunk)[130](index=130&type=chunk)[132](index=132&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on financial condition and results of operations, covering strategy, recent developments, operating results, and liquidity [Executive Overview and Strategy](index=37&type=section&id=Executive%20Overview%20and%20Strategy) Management outlines the company's strategy, centered on scaling the Rare Disease platform and strengthening the Generics and Established Brands segment - The company's core strategy is to deliver sustainable growth by scaling its Rare Disease business, led by Cortrophin Gel, and strengthening its Generics business through enhanced development and focus on niche opportunities[165](index=165&type=chunk)[166](index=166&type=chunk) - The pending acquisition of Alimera is a key strategic move intended to strengthen the Rare Disease business and expand the company's footprint internationally into Europe, Asia, and the Middle East[167](index=167&type=chunk) - The company continues to invest in its Rare Disease platform to support growth in new areas like pulmonology, ophthalmology, and gout for its ACTH products[168](index=168&type=chunk) [Results of Operations](index=40&type=section&id=Results%20of%20Operations) This subsection provides a detailed comparative analysis of financial performance, breaking down changes in revenues, costs, and expenses Q2 2024 vs. Q2 2023 Revenue Performance (in thousands) | Segment | Q2 2024 Revenue | Q2 2023 Revenue | % Change | | :--- | :--- | :--- | :--- | | Generic pharmaceutical products | $73,964 | $63,317 | 16.8% | | Established brands, royalties, etc. | $14,883 | $28,926 | (48.5)% | | Rare disease pharmaceutical products | $49,193 | $24,304 | 102.4% | | **Total Net Revenues** | **$138,040** | **$116,547** | **18.4%** | - The **102.4% increase in Rare Disease revenue** was driven by increased volume of Cortrophin Gel in its third year of launch[193](index=193&type=chunk) - Selling, general, and administrative (SG&A) expenses increased by **36.3% to $52.8 million** in Q2 2024, driven by continued investment in the Rare Disease segment, legal expenses, and costs related to the pending Alimera acquisition[197](index=197&type=chunk) - For the six months ended June 30, 2024, net income was **$15.9 million**, a significant increase from **$7.7 million** in the prior year period, boosted by a **$5.3 million gain** on the sale of the Oakville property and a **$6.9 million unrealized gain** on an equity investment[15](index=15&type=chunk)[216](index=216&type=chunk)[218](index=218&type=chunk) [Liquidity and Capital Resources](index=49&type=section&id=Liquidity%20and%20Capital%20Resources) The company details its sources of liquidity, including cash from operations and credit facilities, and analyzes cash flow activities - As of June 30, 2024, the company had **$240.1 million in cash and cash equivalents** and **$40.0 million available** under its Revolving Facility[12](index=12&type=chunk)[224](index=224&type=chunk) - The company has secured a commitment for **$280.0 million in debt financing** to fund the pending acquisition of Alimera[225](index=225&type=chunk) Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2024 | 2023 | | :--- | :--- | :--- | | Operating Activities | $35,683 | $42,050 | | Investing Activities | $4,484 | ($9,179) | | Financing Activities | ($21,178) | $75,602 | - Key cash outflows in H1 2024 included a **$12.5 million contingent consideration payment** related to the Novitium acquisition and **$10.0 million for treasury stock purchases** for restricted stock vests[232](index=232&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=50&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states no material changes in its exposure to market risks, including interest rate, equity, and foreign currency exchange rate risks - There have been no material changes in the company's exposure to market risks, including interest rate, equity, and foreign currency exchange rate risk, since the end of the 2023 fiscal year[234](index=234&type=chunk) [Controls and Procedures](index=50&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2024, with no material changes to internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2024[236](index=236&type=chunk) - There were no changes in internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[237](index=237&type=chunk) [PART II — OTHER INFORMATION](index=51&type=section&id=PART%20II%20%E2%80%94OTHER%20INFORMATION) This part covers legal proceedings, new risk factors related to the Alimera acquisition, equity security sales, and other miscellaneous items [Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference legal proceedings detailed in Note 13, covering commercial, patent, and ranitidine-related litigation - This item refers to Note 13, Commitments and Contingencies, for a full description of the company's ongoing legal matters[238](index=238&type=chunk) [Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors) This section introduces new significant risk factors related to the pending Alimera acquisition, including merger completion, debt, international operations, and supply chain - The pending merger with Alimera is subject to conditions beyond the company's control, and failure to complete it could have a material adverse effect on the business and stock price[240](index=240&type=chunk) - The company will incur substantial debt (**$280.0 million committed**) to finance the Alimera acquisition, which could impact future cash flow and operational flexibility[251](index=251&type=chunk) - The acquisition will materially increase international operations, exposing the company to new risks related to foreign regulations, currency exchange, tax laws, and supply chain complexities[256](index=256&type=chunk)[258](index=258&type=chunk) - Post-merger, the company will have increased reliance on single-source third-party manufacturers for Alimera's products, with one key supplier for YUTIQ receiving an FDA warning letter in July 2024, potentially affecting supply[265](index=265&type=chunk)[266](index=266&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=56&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities and discloses share repurchases from employees for tax withholding obligations - There were no sales of unregistered securities during the quarter[269](index=269&type=chunk) Issuer Purchases of Equity Securities (Q2 2024) | Period | Total Number of Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | April 2024 | 13,259 | $66.92 | | May 2024 | 5,816 | $65.02 | | June 2024 | 553 | $62.62 | | **Total** | **19,628** | **$66.23** | - All shares purchased were transferred from employees to satisfy tax withholding obligations on vested restricted stock awards and were not part of a formal repurchase plan[270](index=270&type=chunk) [Other Items (3, 4, 5, 6)](index=56&type=section&id=Other%20Items%20(3,%204,%205,%206)) This section confirms no defaults on senior securities, non-applicability of mine safety disclosures, no Rule 10b5-1 trading plan changes, and references exhibits - Item 3: No defaults upon senior securities[271](index=271&type=chunk) - Item 4: Mine Safety Disclosures are not applicable[272](index=272&type=chunk) - Item 5: No directors or executive officers adopted or terminated Rule 10b5-1 trading plans during the quarter[271](index=271&type=chunk) - Item 6: A list of exhibits filed with the Form 10-Q is provided[272](index=272&type=chunk)[273](index=273&type=chunk)

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance • Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% yearover-year • Delivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02 • Net loss available to common shareholders of $(2.7) million and diluted GA ...

[Legal & Financial Disclosures](index=2&type=section&id=1-legal-financial-disclosures) [Disclaimer](index=2&type=section&id=1-1-disclaimer) This section outlines forward-looking statements, emphasizing that actual results may differ materially due to various risks and uncertainties, and states the company undertakes no obligation to update these statements - Forward-looking statements are subject to risks and uncertainties, including commercialization success, regulatory approvals, supply chain disruptions, and economic conditions, which may cause actual results to differ materially[3](index=3&type=chunk) - The company does not undertake any obligation to update or revise forward-looking statements[3](index=3&type=chunk) [Non-GAAP Financial Measures](index=2&type=section&id=1-2-non-gaap-financial-measures) This section defines non-GAAP financial measures like Adjusted EBITDA and Adjusted EPS, explaining their use by management for evaluation and strategic decisions, while clarifying their limitations - Non-GAAP financial measures, including Adjusted EBITDA and Adjusted EPS, are used by management to evaluate performance and make strategic decisions, providing useful information to investors[4](index=4&type=chunk) - These non-GAAP measures are not substitutes for GAAP measures and have limitations due to subjective calculations and potential differences in calculation methods compared to other companies[4](index=4&type=chunk) - The company does not provide a reconciliation for forward-looking non-GAAP measures due to the inability to accurately estimate all variables and adjustments without unreasonable effort[4](index=4&type=chunk) [Company Profile & Strategic Overview](index=3&type=section&id=2-company-profile-strategic-overview) [Business Model and Growth Pillars](index=3&type=section&id=2-1-business-model-growth-pillars) ANI Pharmaceuticals operates with a business model driven by Rare Disease, Generics, and Established Brands, with Purified Cortrophin® Gel as a key growth driver - ANI's business model is driven by three pillars: Rare Disease (lead asset Purified Cortrophin® Gel), Generics (enhanced R&D and operational excellence), and Established Brands (unique commercial capability, high margins, strong cash flow)[7](index=7&type=chunk) 2023 Financial Snapshot | Metric | Value | | :---------------------------- | :------ | | 2023 Revenue | $487 million | | Adjusted non-GAAP EBITDA Growth | 140% | [Historical Performance and Growth Drivers](index=4&type=section&id=2-2-historical-performance-growth-drivers) ANI has consistently achieved high revenue growth since 2021, with the Rare Disease segment, particularly Cortrophin Gel, projected as the primary future growth driver - ANI has consistently delivered high revenue growth since 2021[8](index=8&type=chunk) - Rare Disease is expected to be the largest driver of growth going forward[8](index=8&type=chunk) - Rare Disease contributed to profitability in 2023, in its second year of launch, following 2022 investment in infrastructure[14](index=14&type=chunk) [Q1 2024 Business Highlights](index=6&type=section&id=2-3-q1-2024-business-highlights) In Q1 2024, ANI saw steady gains for Cortrophin Gel across core therapeutic areas and strong traction in new areas, alongside six new generic product launches - Cortrophin Gel achieved steady gains in Q1 2024 across core therapeutic areas (rheumatology, neurology, nephrology) and strong traction in new areas (pulmonology, ophthalmology)[17](index=17&type=chunk) - Cortrophin Gel momentum continued into Q2 2024 with record new patient starts in April and May[17](index=17&type=chunk) - **Six new generic products** were launched in Q1 2024, leveraging operational excellence and U.S.-based manufacturing[17](index=17&type=chunk) [Financial Outlook: 2024 Guidance](index=7&type=section&id=3-financial-outlook-2024-guidance) [2024 Guidance Overview](index=7&type=section&id=3-1-2024-guidance-overview) ANI Pharmaceuticals has reiterated its 2024 guidance, projecting total net revenue between $520 million and $542 million, with strong contributions from Cortrophin Gel 2024 Full Year Guidance vs. 2023 Actuals | Metric | Full Year 2024 Guidance | 2023 Actuals | | :--------------------------- | :---------------------- | :----------- | | Net Revenue (Total Company) | $520 million - $542 million | $487 million | | Cortrophin Gel Net Revenue | $170 million - $180 million | $112 million | | Adjusted Non-GAAP EBITDA | $135 million - $145 million | $134 million | | Adjusted Non-GAAP Diluted EPS | $4.26 - $4.67 | $4.71 | - 2024 guidance for Adjusted Non-GAAP Diluted EPS reflects a full year of shares outstanding from the May 2023 secondary equity raise[23](index=23&type=chunk) [Rare Disease Segment: Cortrophin Gel](index=8&type=section&id=4-rare-disease-segment-cortrophin-gel) [Cortrophin Gel Product & Market Overview](index=8&type=section&id=4-1-cortrophin-gel-product-market-overview) Cortrophin Gel, a purified corticotropin (ACTH), is a treatment for chronic autoimmune disorders in a market with limited competition and significant growth potential - Cortrophin Gel is purified corticotropin (ACTH) for chronic autoimmune disorders, facing limited competition with high barriers to entry[25](index=25&type=chunk)[28](index=28&type=chunk) - The ACTH market was estimated at **$600 million** at Cortrophin Gel's 2022 launch, with a category potential of **~$1.2 billion** for significant future growth[28](index=28&type=chunk) - Cortrophin Gel is approved for multiple indications, initially launched in nephrology and rheumatology, and recently expanded into pulmonology and ophthalmology[28](index=28&type=chunk) [Cortrophin Gel Performance & Market Expansion](index=9&type=section&id=4-2-cortrophin-gel-performance-market-expansion) Cortrophin Gel is ANI's primary growth engine, demonstrating continued prescription growth and active expansion into new therapeutic areas with new product formulations - Cortrophin Gel shows continued prescription growth in original therapeutic areas (neurology, nephrology, rheumatology) and strong prescribing momentum[30](index=30&type=chunk) - The company is gaining traction in new therapeutic areas, adding a second geographical region to the pulmonology sales force in Q1 2024 and deploying a targeted ophthalmology sales force[30](index=30&type=chunk) - A **1-mL vial** size of Cortrophin Gel was launched in Q4 2023, indicated for acute gouty arthritis flares, expanding treatment options[30](index=30&type=chunk) [ACTH Market Dynamics](index=10&type=section&id=4-3-acth-market-dynamics) The overall ACTH market is projected to return to growth in 2024, with Cortrophin Gel expected to maintain a strong multi-year growth trajectory due to significant room for market expansion - The ACTH market is expected to return to growth in 2024, projected to grow **~8-10%+**[32](index=32&type=chunk) - Cortrophin Gel is believed to remain on a strong multi-year growth trajectory[31](index=31&type=chunk) - The number of patients on ACTH therapy today is substantially lower than a few years ago, indicating significant room for growth[32](index=32&type=chunk) ACTH Market Sales ($ millions) | Year | ACTH Market Sales ($ millions) | | :--- | :----------------------------- | | 2019 | $953 million | | 2020 | $768 million | | 2021 | $594 million | | 2022 | $558 million | | 2023 | $537 million | | 2024E | $580 million - $590 million | [Strategic Expansion Initiatives](index=11&type=section&id=4-4-strategic-expansion-initiatives) ANI is actively pursuing M&A and in-licensing opportunities to expand its Rare Disease business, prioritizing existing therapeutic areas and other rare disease segments - ANI is focused on M&A and in-licensing to expand its Rare Disease business[33](index=33&type=chunk)[34](index=34&type=chunk) - Priority 1 opportunities are in existing therapeutic areas: nephrology, neurology, rheumatology, pulmonology, and ophthalmology[34](index=34&type=chunk) - Priority 2 includes rare disease opportunities outside current priority areas where ANI can leverage its Rare Disease platform[34](index=34&type=chunk) [Generics & Established Brands Segment](index=13&type=section&id=5-generics-established-brands-segment) [R&D, New Product Launches & Operational Excellence](index=13&type=section&id=5-1-rd-new-product-launches-operational-excellence) ANI demonstrates superior R&D capabilities and operational excellence, evidenced by new product launches, high CGT approval rankings, and a strong U.S.-based manufacturing footprint - Launched **six new products** in Q1 2024, including a Competitive Generic Therapy (CGT) product with 180-day exclusivity[38](index=38&type=chunk) - Ranks number two in CGT approvals and among the top 15 manufacturers in product approvals[38](index=38&type=chunk) - Increased 2024 R&D spend to fuel new launches and drive high single-digit/low double-digit growth[38](index=38&type=chunk) - Supplied over **1.5 billion doses** of therapeutics in 2023 and maintains excellent compliance with successful FDA audits across all sites, including a Q1 2024 capacity expansion at the New Jersey site[38](index=38&type=chunk)[86](index=86&type=chunk)[87](index=87&type=chunk) - Focuses on cost excellence through systematic reduction of raw materials and finished goods costs, and a lean approach to corporate spending[38](index=38&type=chunk) - U.S.-based manufacturing and operational nimbleness enable quick response to drug shortages and patient needs, establishing ANI as a partner of choice[40](index=40&type=chunk) [Financial Strength](index=12&type=section&id=6-financial-strength) [Balance Sheet and Cash Flow](index=12&type=section&id=6-1-balance-sheet-cash-flow) ANI maintains a strong balance sheet to support its Rare Disease business development, reporting $221 million in cash and a significantly improved net debt to EBITDA ratio of 0.5x as of March 31, 2024 Balance Sheet Metrics | Metric | 2022 | 2023 | | :-------------------------- | :--- | :--- | | Cash & Cash Equivalents | $48 million | $221 million | | Net Debt/EBITDA | 4.4x | 0.5x | | Gross Debt | $297 million | $294 million | | Net Debt | $249 million | $73 million | | Adjusted Non-GAAP EBITDA (1) | $56 million | $134 million | - Strong balance sheet supports Rare Disease business development[37](index=37&type=chunk) [Leadership Team](index=15&type=section&id=7-leadership-team) [Executive Management](index=15&type=section&id=7-1-executive-management) ANI Pharmaceuticals is led by an experienced and purpose-driven management team with extensive expertise in pharmaceuticals and healthcare, including key executives across various functions - Nikhil Lalwani, President & CEO, has over **20 years** of leadership experience in pharmaceuticals and a proven track record of strategic growth[89](index=89&type=chunk) - Chris Mutz, Head of Rare Diseases, brings over **25 years** of commercialization experience, including building and leading the launch of Soliris[89](index=89&type=chunk) - Samy Shanmugam, COO & Head of Global R&D, has extensive R&D and operations experience, having developed over **100 specialty dosage forms** and ANDAs[89](index=89&type=chunk) - The leadership team includes experienced professionals in finance (Stephen Carey), HR (Krista Davis), legal (Meredith Cook), generics (Ori Gutwerg), corporate development (Chad Gassert), and operations (James Marken)[89](index=89&type=chunk)[90](index=90&type=chunk) [Key Investment Highlights](index=16&type=section&id=8-key-investment-highlights) [Investment Summary](index=16&type=section&id=8-1-investment-summary) ANI Pharmaceuticals presents a compelling investment case driven by its strong and growing Rare Disease business, robust Generics segment, solid financial strength, and an experienced management team - Strong and growing Rare Disease business, with Cortrophin Gel forecasted at **$170 million - $180 million** revenues in 2024 (**+52% - 61%**) and significant multi-year future growth opportunity[91](index=91&type=chunk) - Robust and nimble Generics segment with targeted growth in the high single-digit to low double-digit range, driven by R&D excellence and reliable supply from U.S. manufacturing[91](index=91&type=chunk) Financial Strength Highlights | Metric | Value (as of March 31, 2024) | | :-------------------------------- | :--------------------------- | | Unrestricted Cash | $229 million | | 2023 Cash Flow from Operations | $119 million | | Estimated 2024 Revenue | $520 million - $542 million (7% - 11% YoY growth) | | Estimated 2024 Adjusted non-GAAP EBITDA | $135 million - $145 million | | Estimated 2024 Adjusted non-GAAP EPS | $4.26 - $4.67 | - Experienced, purpose-driven management team with deep expertise across Rare Disease, Generics, and Established Brands, focused on serving patients[91](index=91&type=chunk) [Appendix: Non-GAAP Reconciliations](index=18&type=section&id=9-appendix-non-gaap-reconciliations) [Adjusted non-GAAP EBITDA Reconciliation](index=18&type=section&id=9-1-adjusted-non-gaap-ebitda-reconciliation) This section provides a detailed reconciliation of Net Income to Adjusted non-GAAP EBITDA for the three months ended March 31, 2024, and 2023, including various non-recurring and non-cash adjustments Adjusted non-GAAP EBITDA Reconciliation (Three Months Ended March 31) | Metric | 2024 ($) | 2023 ($) | | :------------------------------------------ | :--------- | :--------- | | Net Income | 18,207 | 1,439 | | Interest expense, net | 4,600 | 7,696 | | Provision for income taxes | 7,128 | 726 | | Depreciation and amortization | 14,686 | 14,700 | | Contingent consideration fair value adjustment | 90 | 961 | | Restructuring activities | - | 1,130 | | Gain on sale of building | (5,347) | - | | Unrealized gain on investment in equity securities | (9,655) | - | | Impact of Canada operations | - | 1,647 | | Stock-based compensation | 6,934 | 4,338 | | Novitium transaction expenses | 713 | 342 | | Litigation expenses | 245 | - | | **Adjusted non-GAAP EBITDA** | **37,633** | **33,013** | [Adjusted non-GAAP EPS Reconciliation](index=19&type=section&id=9-2-adjusted-non-gaap-eps-reconciliation) This section details the reconciliation of Net Income Available to Common Shareholders to Adjusted non-GAAP Diluted EPS for the three months ended March 31, 2024, and 2023, with adjustments for non-cash and non-recurring items Adjusted non-GAAP EPS Reconciliation (Three Months Ended March 31) | Metric | 2024 ($) | 2023 ($) | | :-------------------------------------------------- | :--------- | :--------- | | Net Income Available to Common Shareholders | 17,801 | 1,033 | | Non-cash interest (income) expense | (10) | 987 | | Depreciation and amortization | 14,686 | 14,700 | | Contingent consideration fair value adjustment | 90 | 961 | | Restructuring activities | - | 1,130 | | Gain on sale of building | (5,347) | - | | Unrealized gain on investment in equity securities | (9,655) | - | | Impact of Canada operations | - | 1,647 | | Stock-based compensation | 6,934 | 4,338 | | Novitium transaction expenses | 713 | 342 | | Litigation expenses | 245 | - | | Less: Estimated tax impact of adjustments | (1,991) | (5,785) | | **Adjusted non-GAAP Net Income Available to Common Shareholders** | **23,466** | **19,353** | | Diluted Weighted-Average Shares Outstanding | 19,422 | 16,531 | | **Adjusted non-GAAP Diluted Earnings per Share** | **1.21** | **1.17** |

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President and Chief Executive Officer Stephen Carey - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Leszek Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Timothy Chiang - Capital One Operator Good day, ...

[PART I — FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20%E2%80%94FINANCIAL%20INFORMATION) [Condensed Consolidated Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) The unaudited statements for Q1 2024 show significant growth in net revenues and net income compared to the prior year Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total Assets** | **$914,524** | **$904,422** | | Cash and cash equivalents | $228,597 | $221,121 | | Accounts receivable, net | $172,418 | $162,079 | | Inventories | $113,837 | $111,196 | | Intangible assets, net | $196,044 | $209,009 | | **Total Liabilities** | **$437,711** | **$446,823** | | Non-current debt, net | $284,607 | $284,819 | | **Total Stockholders' Equity** | **$451,963** | **$432,749** | Condensed Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | **Net Revenues** | **$137,430** | **$106,786** | | Operating Income | $20,312 | $9,895 | | **Net Income** | **$18,207** | **$1,439** | | Net Income Available to Common Shareholders | $17,801 | $1,033 | | **Diluted Income Per Share** | **$0.82** | **$0.06** | [Note 1. Business, Presentation, and Recent Accounting Pronouncements](index=10&type=section&id=Note%201.%20Business%2C%20Presentation%2C%20and%20Recent%20Accounting%20Pronouncements) The company is a diversified bio-pharmaceutical firm focused on Rare Disease and generics with U.S. manufacturing - The company's strategic focus is on scaling its **Rare Disease business**, strengthening its **generics portfolio**, and leveraging its **U.S.-based manufacturing capabilities**[26](index=26&type=chunk) - The Oakville, Ontario, Canada site was sold on March 28, 2024, for approximately **$14.2 million** as part of initiatives to capture operational synergies[26](index=26&type=chunk) [Note 2. Revenue Recognition and Related Allowances](index=13&type=section&id=Note%202.%20Revenue%20Recognition%20and%20Related%20Allowances) Revenue is primarily from pharmaceutical sales, with four customers accounting for 70% of net revenues in Q1 2024 Disaggregation of Revenue (in thousands) | Products and Services | March 31, 2024 | March 31, 2023 | | :--- | :--- | :--- | | Sales of generic pharmaceutical products | $70,217 | $63,713 | | Sales of established brand products, royalties, etc. | $30,276 | $26,743 | | Sales of rare disease pharmaceutical products | $36,937 | $16,330 | | **Total net revenues** | **$137,430** | **$106,786** | - In Q1 2024, four customers accounted for 34%, 13%, 10%, and 13% of net revenues, respectively, totaling **70% of net revenues**[49](index=49&type=chunk)[50](index=50&type=chunk) [Note 3. Restructuring](index=15&type=section&id=Note%203.%20Restructuring) The company sold its Oakville, Canada manufacturing plant in March 2024, resulting in a $5.3 million gain - The sale of the Oakville property was completed on March 28, 2024, generating a gain of approximately **$5.3 million**[54](index=54&type=chunk) [Note 4. Indebtedness](index=15&type=section&id=Note%204.%20Indebtedness) The company's total outstanding principal on its senior secured term loan was $293.3 million as of March 31, 2024 Term Facility Debt Summary (in thousands) | Component | March 31, 2024 | | :--- | :--- | | Non-current borrowing on debt | $290,250 | | Deferred financing costs | ($5,643) | | **Non-current debt, net** | **$284,607** | - The outstanding principal on the Term Facility was **$293.3 million** as of March 31, 2024, while the **$40.0 million** Revolving Facility was undrawn[58](index=58&type=chunk)[60](index=60&type=chunk) [Note 5. Derivative Financial Instrument and Hedging Activity](index=17&type=section&id=Note%205.%20Derivative%20Financial%20Instrument%20and%20Hedging%20Activity) An interest rate swap with a notional amount of $139.4 million is used to hedge against variable interest rate risk - The interest rate swap is designated as an effective cash flow hedge, with a notional amount of **$139.4 million** and a fair value asset of **$7.7 million** as of March 31, 2024[67](index=67&type=chunk) [Note 6. Earnings Per Share](index=18&type=section&id=Note%206.%20Earnings%20Per%20Share) Earnings per share increased significantly in Q1 2024, driven by higher net income Earnings Per Share Comparison | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Basic EPS | $0.84 | $0.06 | | Diluted EPS | $0.82 | $0.06 | [Note 8. Goodwill and Intangible Assets](index=19&type=section&id=Note%208.%20Goodwill%20and%20Intangible%20Assets) Net intangible assets totaled $196.0 million as of March 31, 2024, with no impairment charges recognized Intangible Assets Summary (in thousands) | Asset Type | Net Carrying Amount (Mar 31, 2024) | | :--- | :--- | | Acquired ANDAs | $103,079 | | NDAs and product rights | $54,215 | | Customer relationships | $16,305 | | In process research and development (IPR&D) | $19,800 | | **Total Intangible Assets, net** | **$196,044** | - Amortization expense for definite-lived intangibles was **$13.0 million** for the three months ended March 31, 2024, and no impairment losses were recognized[83](index=83&type=chunk) [Note 12. Commitments and Contingencies](index=25&type=section&id=Note%2012.%20Commitments%20and%20Contingencies) The company faces various legal proceedings and regulatory risks related to certain marketed products - Four products are marketed without approved NDAs or ANDAs, generating **$4.1 million** in net revenues in Q1 2024[114](index=114&type=chunk) - In March 2024, ANI initiated a civil action against CG Oncology, Inc. to enforce a **5% running royalty obligation** on worldwide net sales of cretostimogene[122](index=122&type=chunk) - The company is a defendant in ongoing **ranitidine-related litigation** in both federal and state courts[126](index=126&type=chunk)[127](index=127&type=chunk) [Note 13. Fair Value Disclosures](index=29&type=section&id=Note%2013.%20Fair%20Value%20Disclosures) Fair value measurements include an investment in CG Oncology valued at $9.7 million and contingent consideration of $11.6 million - The company holds 219,925 shares of CG Oncology (Nasdaq: CGON), which had a fair value of **$9.7 million** as of March 31, 2024[135](index=135&type=chunk) - The fair value of the contingent consideration liability from the Novitium acquisition decreased to **$11.6 million** from $24.0 million, primarily due to a **$12.5 million payment**[137](index=137&type=chunk)[140](index=140&type=chunk) [Note 15. Segment Reporting](index=32&type=section&id=Note%2015.%20Segment%20Reporting) The Rare Disease segment revenue grew 126% year-over-year, while the Generics segment also showed solid growth Segment Net Revenues (in thousands) | Segment | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Generics, Established Brands, and Other | $100,493 | $90,456 | | Rare Disease | $36,937 | $16,330 | | **Total net revenues** | **$137,430** | **$106,786** | Segment EBITDA (in thousands) | Segment | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Generics, Established Brands, and Other | $45,306 | $38,828 | | Rare Disease | $396 | ($1,251) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's discussion highlights a 28.7% revenue increase in Q1 2024, driven by strong segment performance - The company's growth strategy is focused on its **Rare Disease platform** and strengthening its **Generics segment** with niche opportunities[158](index=158&type=chunk)[161](index=161&type=chunk) - The sale of the Oakville, Ontario property was completed on March 28, 2024, resulting in net cash proceeds of approximately **$13.5 million** and a gain on sale of **$5.3 million**[165](index=165&type=chunk) [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Net revenues increased 28.7% to $137.4 million in Q1 2024, with rare disease product revenues surging 126.2% Net Revenues Change by Segment (in thousands) | Segment | Q1 2024 | Q1 2023 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Generic pharmaceutical products | $70,217 | $63,713 | $6,504 | 10.2% | | Established brand products, etc. | $30,276 | $26,743 | $3,533 | 13.2% | | Rare disease pharmaceutical products | $36,937 | $16,330 | $20,607 | 126.2% | | **Total net revenues** | **$137,430** | **$106,786** | **$30,644** | **28.7%** | - The increase in rare disease revenue was driven by **increased volume of Cortrophin Gel** in its third year of launch[176](index=176&type=chunk) - Selling, general, and administrative expenses increased by **$11.6 million (31.7%)** due to higher employment costs and investment in the Rare Disease segment[182](index=182&type=chunk) [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintained a strong liquidity position with $228.6 million in cash and cash equivalents as of March 31, 2024 Summary of Cash Flows (in thousands) | Activity | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Operating Activities | $18,269 | $21,424 | | Investing Activities | $8,933 | ($2,353) | | Financing Activities | ($19,726) | ($4,548) | - The company has **$40.0 million available** for borrowing under its revolving credit facility as of March 31, 2024[193](index=193&type=chunk)[194](index=194&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks remain interest rate, equity, and foreign currency exchange rate risk - The most significant market risks identified are **interest rate risk, equity risk, and foreign currency exchange rate risk**, with no material changes reported[203](index=203&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2024 - Based on an evaluation as of March 31, 2024, the principal executive and financial officers concluded that **disclosure controls and procedures were effective**[205](index=205&type=chunk) - **No material changes** in internal control over financial reporting occurred during the quarter[206](index=206&type=chunk) [PART II — OTHER INFORMATION](index=43&type=section&id=PART%20II%20%E2%80%94OTHER%20INFORMATION) [Legal Proceedings](index=43&type=section&id=Item%201.%20Legal%20Proceedings) Details regarding ongoing legal proceedings are provided in Note 12 of the financial statements - For details on legal proceedings, the report refers to **Note 12, Commitments and Contingencies**, in the financial statements[207](index=207&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the risk factors disclosed in the 2023 Annual Report on Form 10-K have occurred - The company directs investors to the Risk Factors section of its **2023 Annual Report on Form 10-K**, indicating no material changes[208](index=208&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company purchased 129,016 shares from employees to satisfy tax withholding obligations for vested stock awards Issuer Purchases of Equity Securities (Q1 2024) | Period | Total Number of Shares Purchased | | :--- | :--- | | January 2024 | 3,320 | | February 2024 | 49,066 | | March 2024 | 76,630 | | **Total** | **129,016** | - The shares purchased were acquired from employees to cover **minimum tax withholding obligations** and were not part of a publicly announced repurchase plan[211](index=211&type=chunk)